Skip to main content
. 2012 Oct 29;13(11):13926–13948. doi: 10.3390/ijms131113926

Figure 2.

Figure 2

Biomarker discovery approaches in clinical proteomics. Samples (normal vs. diseased or drug-treated vs. untreated) are fractionated and then Mass Spectrometry (MS)-analyzed according to three main strategies. (a) Molecular profiling aimed to the generation and comparative analysis of fingerprints between healthy/diseased or drug-treated/untreated biospecimen. (b) High Performance Liquid Chromatography coupled to Mass Spectrometry (LC-MS/MS) for both quantitation and identification of protein. (c) Mono-or bi-dimensional Gel Electrophoresis (1DE or 2DE) followed by identification of bands or spots in which quantitative variations of protein expression are observed.